Multiple targets are currently being investigated for CAR T cell therapy in solid tumors, mainly overexpressed surface proteins and glycoproteins such as human epidermal growth factor receptor 2 (HER-2) for breast, lung, ovarian, and pancreatic cancer; carcinoembryonic antigen (CEA) for lung and digestive malignancies; MUC for pancreatic, gastric, and OC; epidermal growth factor receptor for glioblastoma and pancreatic cancer; and prostate-specific membrane antigen (PSMA) for prostate cancer, among others. The gene discussed is CEACAM5; the disease is prostate cancer.